Sanwa Kagaku Kenkyusho Co., Ltd.

Nippon Oil Fats Co., Ltd.

Sekisui Kagaku Kogyo Kabushiki Kaisha

Tsutomu Ishida

Masayasu Kurono

Makoto Sato

Noboru Tomiya

Shigeaki Yoshina

Takashi Nakagawa

Hitoshi Noda

Kazushi Tokita

Masato Azuma

Hiroko Tsukahara

Katsuhiko Takahashi

Hidehumi Yamakawa

Mitsuji Nakano

Satoshi Uenoyama

Masahiro Fuchigami

Tetsushi Tomoguri

Keizo Nakaya

Satoko Yamashita

Moritaka Goto

The problem to be solved by the present invention is to provide a medicine which is excellent in the treatment of type 2 diabetes, diabetic complications or impaired glucose tolerance. The present invention provides a medicine characterized in that a compound represented by the following general formula (I), a salt thereof, or a solvate thereof, and at least one kind of other diabetic medicine: 

Medicine consisting of concomitant use or combination of DPP-IV inhibitor and other diabetic medicine

The invention provides a polypeptide of calcitonin analogue and use thereof. The polypeptide has such an amino acid sequence that proline-amide residue (Pro-NH.sub.2) at C-terminal of native eel calcitonin is substituted to a homoserine amide residue (Hse.multidot.NH.sub.2).

Calcitonin analogue and use thereof

The modified polypeptide compound of the present invention is represented by the following general formula ((SEQ ID NO: 2)-X):

Modified polypeptide compound with VIP-like activity

A percutaneous-administration-type pharmaceutical preparation of nitroglycerin is provided. The preparation comprises a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is placed on one surface of said backing, wherein said pressure-sensitive adhesive layer contains an alkyl (meth)acrylate (co)polymer in the concentration of 35-85% by weight, nitroglycerin in the concentration of 10-30% by weight, and a silicic acid anhydride in the concentration of 5-20% by weight, said (co)polymer contains as major (co)polymer components alkyl (meth)acrylates with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexyl methacrylate in the concentration of 40-100% by weight based on the total weight of said alkyl (meth)acrylates. The preparation makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for a long period of time. Also, even a compact preparation can supply a sufficient amount of nitroglycerin. Moreover, the preparation can be manufactured at low cost without any complicated process.

Percutaneous-administration-type pharmaceutical preparation of

A percutaneous-administration-type pharmaceutical preparation of nitroglycerin comprising a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is disposed on one surface of the backing, wherein the pressure-sensitive adhesive layer contains alkyl (meth)acrylate copolymer in the concentration of 80-95% by weight and the nitroglycerin in the concentration of 5-20% by weight, said copolymer contains as major copolymer components alkyl (meth)acrylate with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexylmethacrylate in the concentration of 40-90% by weight based on the total weight of said alkyl (meth)acrylates, and the copolymer has a rolling ball tack value of 2 or less. The preparation obtained makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for long periods of time.

Growing community of inventors

Nagoya, Japan

Tsutomu Ishida